Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert F Storey

Showing results (321-330 of 401) with videos related to

Pageof 41
Sort By:
European Heart Journal|December 8, 2019
Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54Remo H M Furtado, Jose C Nicolau, Giulia Magnani, et al.
Journal of the American Heart Association|August 19, 2020
Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) TrialIda Gregersen, Annika E Michelsen, Ngoc Nguyen Lunde, et al.
European Heart Journal|December 11, 2014
Expert position paper on air pollution and cardiovascular diseaseDavid E Newby, Pier M Mannucci, Grethe S Tell, et al.
European Heart Journal|October 8, 2015
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trialGiulia Magnani, Robert F Storey, Gabriel Steg, et al.
Journal of the American College of Cardiology|September 9, 2017
Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54Marc P Bonaca, Robert F Storey, Pierre Theroux, et al.
European Heart Journal. Acute Cardiovascular Care|January 3, 2024
Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of Cardiology guidelinesAntonio Landi, Victor Aboyans, Dominick J Angiolillo, et al.
Nature Reviews. Cardiology|July 20, 2023
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosisDiana A Gorog, Jose Luis Ferreiro, Ingo Ahrens, et al.
Nature Reviews. Cardiology|January 14, 2022
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers ColloquiumDiana A Gorog, Robert F Storey, Paul A Gurbel, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|January 31, 2017
Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trialEnrico Fabris, Arnoud Van't Hof, Christian W Hamm, et al.
European Heart Journal|January 30, 2020
Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromesRobert F Storey, Paul A Gurbel, Jurrien Ten Berg, et al.
Pageof 41

Showing results (321-330 of 401) with videos related to

Sort By:
Pageof 41
European Heart Journal|December 8, 2019
Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54Remo H M Furtado, Jose C Nicolau, Giulia Magnani, et al.
Journal of the American Heart Association|August 19, 2020
Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) TrialIda Gregersen, Annika E Michelsen, Ngoc Nguyen Lunde, et al.
European Heart Journal|December 11, 2014
Expert position paper on air pollution and cardiovascular diseaseDavid E Newby, Pier M Mannucci, Grethe S Tell, et al.
European Heart Journal|October 8, 2015
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trialGiulia Magnani, Robert F Storey, Gabriel Steg, et al.
Journal of the American College of Cardiology|September 9, 2017
Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54Marc P Bonaca, Robert F Storey, Pierre Theroux, et al.
European Heart Journal. Acute Cardiovascular Care|January 3, 2024
Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of Cardiology guidelinesAntonio Landi, Victor Aboyans, Dominick J Angiolillo, et al.
Nature Reviews. Cardiology|July 20, 2023
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosisDiana A Gorog, Jose Luis Ferreiro, Ingo Ahrens, et al.
Nature Reviews. Cardiology|January 14, 2022
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers ColloquiumDiana A Gorog, Robert F Storey, Paul A Gurbel, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|January 31, 2017
Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trialEnrico Fabris, Arnoud Van't Hof, Christian W Hamm, et al.
European Heart Journal|January 30, 2020
Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromesRobert F Storey, Paul A Gurbel, Jurrien Ten Berg, et al.
Pageof 41